Drug Trial Radar · NCT07511205
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.
Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
104
Planned (sponsor's estimate)
Start
Mar 30, 2026
Primary completion
Apr 9, 2027
Study completion Nov 17, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- Parexel
- First posted
- Apr 6, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AZD1043 following single and multiple ascending doses in healthy adult participants living with overweight and/or obesity, including participants of Japanese and Chinese descent.
Conditions
- Healthy Participants
- Obesity
Interventions
AZD1043Drug
Single or multiple doses of AZD1043 will be administered.
PlaceboOther
Matching placebo to AZD1043 will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs), serious adverse events (SAEs), AE leading to discontinuation (DAEs), and AEs of special interest (AESIs)Time frame: Part A (SAD): From Day-35 to Day 253; Part B (MAD): From Day 1 to Day 253
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
Research Site
Glendale, California · Recruiting
Research Site
Brooklyn, Maryland · Recruiting
Research Site
Harrow, United Kingdom · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.